2023 Layoff Tracker – Data (As of Oct 26, 2023)

Table 1 is a summary of all the layoffs in the biotech industry so far in 2023. Data source: Biopharma Layoff Tracker 2023 on Biospace¹.

Month	Date	Company	Company Size	Layoff #	Layoff %
Jan	Jan-4	Y-mAbs Therapeutics	100-1000	N/A	35%
	Jan-5	Century Therapeutics	100-1000	N/A	25%
	Jan-6	Elevation Oncology	1-100	N/A	30%
	Jan-9	Calithera Biosciences	100-1000	N/A	most
	Jan-9	Editas Medicine	100-1000	N/A	20%
	Jan-11	Verily Life Sciences	>1000	>200	15%
	Jan-11	Abzena	100-1000	66	N/A
	Jan-12	Akili Interactive Labs	100-1000	46	30%
	Jan-19	ReNeuron	1-100	N/A	40%
	Jan-23	EMD Serono	>1000	133	N/A
	Jan-24	Finch Therapeutics	100-1000	N/A	95%
	Jan-30	Quince Therapeutics	1-100	N/A	47%
	Jan-30	Amgen	>1000	300	N/A
	Jan-31	Instil Bio	100-1000	to 15	N/A
	Jan-31	Inovio	100-1000	N/A	11%
Feb	Feb-1	Evelo Biosciences	1-100	unspecified	N/A
	Feb-3	Eisai Inc.	>1000	91	N/A
	Feb-3	Vyant Bio	1-100	unspecified	N/A
	Feb-3	Medicago	1-100	shut doors	N/A
	Feb-6	Thermo Fisher Scientific	>1000	230	N/A
	Feb-6	Magenta Therapeutics	1-100	56	84%
	Feb-8	Aligos Therapeutics	1-100	N/A	25%
	Feb-9	Eliem Therapeutics	1-100	N/A	55%
	Feb-13	Frequency Therapeutics	1-100	N/A	55%
	Feb-15	Grifols	>1000	2000	N/A
	Feb-21	National Resilience	>1000	213	N/A
	Feb-21	Aileron Therapeutics	1-100	6	N/A
	Feb-22	Graphite Bio	100-1000	N/A	50%
	Feb-22	Impel Pharmaceuticals	100-1000	N/A	16%
	Feb-22	Jounce Therapeutics	100-1000	N/A	57%
	Feb-24	ObsEva	1-100	several	N/A
	Feb-28	Theravance Biopharma	100-1000	N/A	17%
Mar	Mar-1	Novo Nordisk	>1000	86	N/A
	Mar-1	G1 Theapeutics	100-1000	N/A	30%
	Mar-6	atai Life Sciences	100-1000	N/A	30%
	Mar-6	Coherus BioSciences	100-1000	60	N/A
	Mar-7	Thermo Fisher Scientific	>1000	154	N/A
	Mar-8	Neuleukin THerapeutics	1-100	N/A	70%
	Mar-9	Olema Oncology	1-100	N/A	25%
	Mar-15	Vaxart, Inc	100-1000	N/A	27%
	Mar-16	Amgen	>1000	450	N/A
	Mar-20	Ferring pharmaceuticals	>1000	89	N/A
	Mar-20	Evofem Biosciences	1-100	8	N/A
	Mar-23	EMD Serono	>1000	6	N/A
	Mar-23	Genentech, Inc	>1000	271	N/A
	Mar-28	Alector	100-1000	30	N/A
	Mar-28	Applied Molecular Transport, Inc.	1-100	N/A	57%
	Mar-28	Satsuma Pharmaceuticals	1-100	N/A	36%
	Mar-28	9 Meters Biopharma	1-100	N/A	50%
	March 31	Molecular Templates	100-1000	N/A	50%
Apr	Apr-3	NGM Biopharmaceuticals	100-1000	75	33%
	Apr-6	Thermo Fisher Scientific	>1000	113	N/A
	Apr-6	LumiraDx	100-1000	N/A	40%
	Apr-7	Pear Therapeutics	100-1000	170	92%
	Apr-10	Biogen	>1000	unspecified	N/A
	Apr-12	Aeglea Biotherapeutics	1-100	to 10	N/A
	Apr-12	Oncocyte Corporation	1-100	N/A	20%
	Apr-14	Talaris Therapeutics	1-100	80	95%
	Apr-17	Emerald Cloud Lab	100-1000	30	N/A
	Apr-17	Nektar Therapeutics	100-1000	N/A	60%
	Apr-20	Foundation Medicine, Inc	>1000	135	N/A
	Apr-20	Enzyvant Therapeutics	1-100	20	N/A
	Apr-26	Thermo Fisher Scientific	>1000	218	N/A
	Apr-26	Sangamo Therapeutics	100-1000	120	27%
	Apr-26	Evelo Biosciences	1-100	unspecified	N/A
	Apr-27	Transplant Genomics	1-100	9	N/A
	Apr-27	Sumitomo	>1000	122	N/A
	Apr-27	Cepheid	>1000	625	N/A
	Apr-27	Care Access	100-1000	N/A	50%
May	May-3	Zymergen	100-1000	27	N/A
	May-4	Selecta Biosceinces	1-100	N/A	25%
	May-8	Takeda	>1000	186	N/A
	May-8	Bristol Myers Squibb	>1000	48	N/A
	May-8	EQRx	100-1000	170	N/A
	May-8	Mammoth Biosciences	100-1000	35	N/A
	May-9	Novavax	>1000	500	25%
	May-9	Gossamer Bio	100-1000	N/A	25%
	May-9	ADC Therapeutics	100-1000	54	17%
	May-10	Roche	>1000	165	N/A
	May-11	Adaptive Phage Therapeutics, Inc.	1-100	22	23%
	May-16	GeneDx	>1000	19	N/A
	May-19	Urovant Sciences	100-1000	22	N/A
	May-23	Affimed	100-1000	N/A	25%
	May-24	Takeda	>1000	27	N/A
	May-24	PTC Therapeutics, Inc.	>1000	N/A	8%
	May-31	Rain Oncology	1-100	N/A	65%
Jun	Jun-2	Oncorus	1-100	55	N/A
	Jun-2	Roche	>1000	unspecified	N/A
	Jun-2	Catalent	>1000	150	N/A
	Jun-5	GreenLight Biosciences	100-1000	96	N/A
	Jun-12	Rejuvenate Bio	1-100	unspecified	N/A
	Jun-14	Encoded Therapeutics	100-1000	N/A	10%
	Jun-20	Thermo Fisher Scientific	>1000	88	N/A
	Jun-20	Molecular Templates	100-1000	N/A	44%
	Jun-20	Twist Bioscience	100-1000	212	N/A
	Jun-21	Nutcracker Therapeutics	1-100	12	N/A
	Jun-22	Federation Bio	1-100	unspecified	N/A
	Jun-26	Intercept Pharmaceuticals	100-1000	N/A	33%
	Jun-27	Illumina	>1000	unspecified	N/A
	Jun-30	Bellerophon Therapeutics	1-100	substantially all	N/A
	Jun-30	Eiger BioPharmaceuticals	1-100	N/A	25%
Jul	Jul-5	Zymergen	100-1000	3	N/A
	Jul-6	Sumitomo Pharma America	>1000	62	N/A
	Jul-7	TrueBinding	100-1000	unspecified	N/A
	Jul-7	Galvanize Therapeutics	100-1000	unspecified	N/A
	Jul-12	Capsida Biotherapeutics	1-100	unspecified	maybe 25%
	Jul-12	Sagent Pharmaceuticals	100-1000	81	N/A
	Jul-12	AVROBIO	100-1000	N/A	50%
	Jul-12	Theratechnologies	1-100	unspecified	N/A
	Jul-12	BAKX Therapeutics	1-100	almost all	N/A
	Jul-19	Amgen	>1000	4	N/A
	Jul-19	FibroGen	100-1000	104	32%
	Jul-19	Amarin Corporation PLC	100-1000	all sales in US, 30% non-sales roles
	Jul-19	Pieris Pharmaceuticals	100-1000	N/A	70%
	Jul-21	Illumina	>1000	151	N/A
	Jul-21	Eliem Therapeutics	1-100	unspecified	N/A
	Jul-21	Idorsia	>1000	500	N/A
	Jul-21	Codexis	100-1000	N/A	25%
	Jul-21	Passage Bio	100-1000	N/A	26%
	Jul-24	Heron Therapeutics	100-1000	N/A	25%
	Jul-25	Biogen	>1000	1000	11%
	Jul-25	Infinity Pharmaceuticals	1-100	21	78%
	Jul-27	Mersana Therapeutics	100-1000	N/A	50%
	Jul-28	Homology Medicines	100-1000	N/A	87%
	Jul-28	Ribon Therapeutics	1-100	unspecified	N/A
Aug	Aug-2	SterRx	100-1000	161	N/A
	Aug-2	Charles River Laboratories	>1000	55	N/A
	Aug-2	Intergalactic Therapeutics	1-100	all	N/A
	Aug-2	Karyopharm Therapeutics	100-1000	80	20%
	Aug-3	Celsius Therapeutics	1-100		67%
	Aug-8	Curebase	100-1000	unspecified	N/A
	Aug-8	Emergent BioSolutions	>1000	400	N/A
	Aug-8	Salarius Pharmaceuticals	1-100	N/A	>50%
	Aug-9	INOVIO Pharmaceuticals	100-1000	58	N/A
	Aug-9	Galera Therapeutics	1-100	N/A	70%
	Aug-10	Atreca	100-1000	N/A	40%
	Aug-14	Bristol Myers Squibb	>1000	108	N/A
	Aug-14	BioXcel Therapeutics	100-1000	110	N/A
	Aug-15	Alaunos Therapeutics	1-100	N/A	60%
	Aug-15	Thermo Fisher Scientific	>1000	205	N/A
	Aug-18	BlueRock Therapeutics	100-1000	50	12%
	Aug-22	Aravive	1-100	23	70%
	Aug-22	Lava Therapeutics	1-100	N/A	36%
	Aug-23	Novartis	>1000	103	N/A
	Aug-24	Agenus	100-1000	N/A	25%
	Aug-24	Pfizer	>1000	69	N/A
	Aug-29	Apellis Pharmaceuticals	100-1000	225	25%
	Aug-31	Sage Therapeutics	100-1000	N/A	40%
	Aug-31	Sana Biotechnology	100-1000	unspecified	N/A
	Aug-31	Nexlmmune	1-100	25	53%
Sep	Sep-5	Infinity Pharmaceuticals	1-100	6	N/A
	Sep-6	CSL Vifor	100-1000	85	N/A
	Sep-11	Enlivex Therapeutics	1-100	N/A	50%
	Sep-12	2seventy bio	100-1000	176	40%
	Sep-15	Lyndra Therapeutics	100-1000	N/A	25%
	Sep-18	Kinnate Biopharma	1-100	N/A	70%
	Sep-18	Histogen	1-100	most	N/A
	Sep-19	Fresh Tracks Therapeutics	1-100	most	N/A
	Sep-19	NightHawk Biosciences	1-100	13	14%
	Sep-22	ImmunityBio	100-1000	48	N/A
	Sep-26	Poxel	1-100	22	N/A
	Sep-26	AM-Pharma	1-100	unspecified	N/A
	Sep-26	Galecto	1-100	30	70%
	Sep-28	PTC Therapeutics, Inc.	>1000	N/A	25%
Oct	Oct-2	Syros Pharmaceuticals	100-1000	N/A	35%
	Oct-3	Kezar Life Sciences	1-100	N/A	41%
	Oct-5	uniQure	100-1000	114	20%
	Oct-5	Atsena Therapeutics	1-100	unspecified	N/A
	Oct-7	Eikon Therapeutics	100-1000	unspecified	N/A
	Oct-9	Biogen	>1000	113	N/A
	Oct-11	Sana Biotechnology	100-1000	120	29%
	Oct-13	Pfizer	>1000	unspecified	N/A
	Oct-16	Nkarta	100-1000	18	10%
	Oct-19	Beam Therapeutics	100-1000	100	20%
	Oct-24	Idorsia Pharmaceuticals	>1000	475	N/A
	Oct-24	BrainStorm Cell Therapeutics	1-100	N/A	30%
	Oct-24	Amgen	>1000	350	N/A
	Oct-26	ElevatedBio	100-1000	N/A	13%

Table 1. 2023 layoff summary

Reference:

https://www.biospace.com/article/biospace-layoff-tracker-2023-athenex-shutters-facility-cuts-staff/

Leave a Reply Cancel reply